Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
Mexico’s Genomma Lab Internacional SAB de CV reported OTC sales up by 32.2% to MXN1.96bn ($86.9m) in the second quarter of 2020 as turnover advanced significantly two of its three reporting regions.
New product launches and increasing numbers of points of sale for its OTC products had been behind the strong
“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn
Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.
Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.
As largest provider of private label/store brand OTCs with “100 plus molecules across 100% price point coverage,” CEO Patrick Lockwood-Taylor says Perrigo’s in position to capitalize as consumers become “more cautious” and look for lower-priced products.
Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.
A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.
Private equity firm CD&R takes control of Opella while Sanofi retains a sizeable stake and nets €10bn.
